Skip to main content
. 2023 Nov 15;13(11):5455–5465.

Figure 1.

Figure 1

Flow diagram of HCC patients with PVTT and APFs who underwent HAIC combined with lenvatinib plus PD-1 inhibitors or TACE combined with lenvatinib plus PD-1 inhibitors. HCC: hepatocellular carcinoma; PVTT: portal vein tumor thrombosis; APFs: artery-portal shunts; HAIC: hepatic arterial infusion chemotherapy; TACE: transarterial chemoembolization.